J&J Medical Connect
CAPLYTA®

(lumateperone)

This information is intended for US patients and caregivers to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended to promote the use of our products, nor to provide medical advice.

CAPLYTA – What is The Dose of CAPLYTA For Patients With Liver Disease? 

Last Updated: 02/13/2026

summary

Here is a passage from the CAPLYTA PRESCRIBING INFORMATION and MEDICATION GUIDE which may be helpful in addressing your question:

What is the dose of CAPLYTA for patients with liver disease? 

  • The recommended CAPLYTA dosage in patients with moderate liver disease or severe liver disease is 21 mg once daily.1
  • The recommended CAPLYTA dosage in patients with mild liver disease is the same as those with normal liver function.1
  • For reference, the usual recommended oral dosage of CAPLYTA is 42 mg once daily.1

CAPLYTA can be taken with or without food.1

Please refer to your healthcare provider for further questions.

Keep CAPLYTA and all medicines out of reach of children.1 

additional information

This information is provided ONLY in response to your request and is not intended as medical advice, to promote the use of our product, or suggest use in any manner other than as described in the PRESCRIBING INFORMATION. All decisions regarding your medical treatment should be made with your healthcare professional(s). Please contact your healthcare professional(s) to discuss the information in this response.

Please refer to the attached full PRESCRIBING INFORMATION and the MEDICATION GUIDE for CAPLYTA.1

References

1 CAPLYTA (lumateperone) [Prescribing Information]. Bedminster, NJ: Intra-Cellular Therapies, Inc; https://www.intracellulartherapies.com/docs/caplyta_pi.pdf